Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?
Key Points
Grail’s stock crashed after Galleri’s NHS England trial missed its primary endpoint.
But it’s still generating plenty of revenue without an FDA approval.
- 10 stocks we like better than Grail ›
Grail (NASDAQ: GRAL), which was spun off from Illumina (NASDAQ: ILMN) in 2024, reached a record high of $116.06 on Jan. 22. But today, the cancer test developer's stock trades at just under $70. Is it a buy, sell, or hold at these levels?
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
The bulls vs. the bears
Grail's Galleri blood test aims to detect signals from dozens of cancers before any symptoms appear. That seems like a game changer for the oncology market, but its stock plunged in February after its largest NHS England trial failed to meet its primary endpoint. That trial was considered a crucial stepping stone toward an FDA approval in the U.S. -- which would clear the way for private insurance and Medicare plans to cover its tests.
However, Grail already sells Galleri on a cash-only basis (for $749 to $949) to independent customers, select employers, hospital pilots, and telehealth programs. Its NHS England trial also wasn't a complete failure: Galleri's users in the trial still had fewer Stage IV cancers detected, and it achieved earlier (Stage I and II) detection of the deadliest cancers.
Even without a near-term FDA approval, analysts expect Grail's revenue to grow from $147 million in 2025 to $281 million in 2028. It won't generate a profit anytime soon, and its stock isn't cheap at 17 times this year's sales, but an FDA approval could help it crush those estimates. Therefore, I think it's smarter to buy and hold Grail at under $70 than to hastily sell it.
Should you buy stock in Grail right now?
Before you buy stock in Grail, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Grail wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $386,727!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,232,139!*
Now, it’s worth noting Stock Advisor’s total average return is 906% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 1, 2026.
Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Illumina. The Motley Fool recommends Grail. The Motley Fool has a disclosure policy.
Recommended Articles
